These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23510540)

  • 1. Kinetics of measles antibody by hemagglutination inhibition assay in children in south-west and north-central Nigeria.
    Onoja AB; Adeniji AJ
    Int J Infect Dis; 2013 Jul; 17(7):e552-5. PubMed ID: 23510540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of measles hemagglutination inhibiting antibody levels among school children in Ibadan, Nigeria.
    Ogundiji OT; Okonko IO; Adu FD
    J Immunoassay Immunochem; 2013; 34(2):208-17. PubMed ID: 23537304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles outbreak in Ibadan: clinical, serological and virological identification of affected children in selected hospitals.
    Adu FD; Ikusika A; Omotade O
    J Infect; 1997 Nov; 35(3):241-5. PubMed ID: 9459395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles HI-antibody levels in Lagos children, Nigeria: a follow-up study to resurgence of measles in Lagos metropolis.
    Oyefolu AO; Omilabu SA
    West Afr J Med; 2001; 20(3):238-42. PubMed ID: 11922159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of haemagglutination inhibition antibodies on measles virus replication.
    Odama LE; Eghafona NO; Emejuaiwe SO
    Microbios; 1985; 43(174-175):181-3. PubMed ID: 4094569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
    Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
    J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age.
    Martins C; Garly ML; Bale C; Rodrigues A; Njie-Jobe J; Benn CS; Whittle H; Aaby P
    J Infect Dis; 2014 Sep; 210(5):693-700. PubMed ID: 24688075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
    Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
    J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
    Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
    Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa.
    Whittle HC; Aaby P; Samb B; Jensen H; Bennett J; Simondon F
    Lancet; 1999 Jan; 353(9147):98-102. PubMed ID: 10023894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune status following measles vaccination in infants and evaluation for the need of revaccination.
    Dutta AK; Singhal PK; Khare S; Kumari S; Mathur R; Mullick DN
    Indian Pediatr; 1989 Aug; 26(8):765-72. PubMed ID: 2620977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination.
    Dilraj A; Sukhoo R; Cutts FT; Bennett JV
    Vaccine; 2007 May; 25(21):4170-4. PubMed ID: 17408818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles immunity and response to revaccination of a young adult population in Israel.
    Mendelson E; Duvdevani P; Varsano N; Lerman Y; Slepon R; Dagan R; Cohen D; Danon Y; Shohat T
    J Med Virol; 1996 Nov; 50(3):249-53. PubMed ID: 8923290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The status of measles after five years of mass vaccination in the USSR.
    Burgasov PN; Andzaparidze OG; Popov VF
    Bull World Health Organ; 1973; 49(6):571-6. PubMed ID: 4548384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A study on the level of antibody against measles through maternal-fetal transfer and the immuno-response to measles vaccine among 4 to 7 month olds].
    Liu BY; Feng ZX; Xu AQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Oct; 16(5):263-5. PubMed ID: 8706090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles virus haemagglutination-inhibition antibodies among pregnant and non-pregnant women in the vaccine era in Harare, Zimbabwe.
    Obi CL; Tswana SA; Moyo SR; Berejena C
    Cent Afr J Med; 1996 May; 42(5):135-8. PubMed ID: 8771931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.